Bicalutamide in Treatment of Androgen Receptor (AR) Positive Metastatic Triple Negative Breast Cancer

NCT03055312 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Triple Negative Breast Cancer

Interventions

DRUG: TPC
DRUG: Bicalutamide 150 mg

Sponsor

Sun Yat-sen University